Onboard, tethered IL-12 boosts potency of the Tmod NOT gate and preserves selectivity
Background To reach their full potential in cancer therapy, immune cells engineered with synthetic constructs must achieve the challenging dual objectives of potency and selectivity to overcome the key obstacle: non-specific cytotoxicity. These problems are especially challenging for solid tumor the...
Guardat en:
| Autors principals: | , , , , , , , , , , , |
|---|---|
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
BMJ Publishing Group
2025-05-01
|
| Col·lecció: | Journal for ImmunoTherapy of Cancer |
| Accés en línia: | https://jitc.bmj.com/content/13/5/e010976.full |
| Etiquetes: |
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|